Editor’s Take: This exclusive BIO 2026 interview covers the announcement of a new offering from SK pharmteco.
SK pharmteco launched SKyvec, a viral vector platform supporting gene therapy programs, at the BIO International Convention in San Diego.
The platform unites three core modalities, adeno-associated virus (AAV), adenoviral, and lentiviral vectors, under one offering. SK pharmteco says this gives therapeutics developers the flexibility to leverage custom and regulatory-ready solutions meeting their programs’ unique requirements.
Talking with SK pharmteco at BIO
At BIO 2026, Contract Pharma spoke with SK pharmteco’s John Lee, PhD. Lee is a company Vice President and Head of the Cell & Gene Therapy Business Unit.
Lee emphasized that the launch integrates development capabilities between North America and Europe. The platform is available at SK pharmteco’s United States and European facilities.
“It is particularly attractive for those customers who are looking to globalize their therapies,” Lee said.
He added that SK pharmteco, like many other companies right now, is concentrating on harmonizing its standards across multiple continents. That can often be a challenge.
“Different sites have different platform processes that then become difficult to transfer from one geography to another,” Lee said. “It’s not impossible, but it typically slows things down.”
More on SKyvec
You can read more of our coverage of SKyvec’s launch, and quotes from Dr. Lee, here.
